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Small fiber neuropathy is a common
feature of Ehlers-Danlos syndromes
ABSTRACT
Objective: To investigate the involvement of small nerve fibers in Ehlers-Danlos syndrome (EDS).
Methods: Patients diagnosed with EDS underwent clinical, neurophysiologic, and skin biopsy
assessment. We recorded sensory symptoms and signs and evaluated presence and severity of
neuropathic pain according to the Douleur Neuropathique 4 (DN4) and ID Pain questionnaires
and the Numeric Rating Scale (NRS). Sensory action potential amplitude and conduction velocity
of sural nerve was recorded. Skin biopsy was performed at distal leg and intraepidermal nerve
fiber density (IENFD) obtained and referred to published sex- and age-adjusted normative refer-
ence values.
Results: Our cohort included 20 adults with joint hypermobility syndrome/hypermobility EDS, 3
patients with vascular EDS, and 1 patient with classic EDS. All except one patient had neuro-
pathic pain according to DN4 and ID Pain questionnaires and reported 7 or more symptoms at
the Small Fiber Neuropathy Symptoms Inventory Questionnaire. Pain intensity was moderate
(NRS$4 and,7) in 8 patients and severe (NRS$7) in 11 patients. Sural nerve conduction study
was normal in all patients. All patients showed a decrease of IENFD consistent with the diagnosis
of small fiber neuropathy (SFN), regardless of the EDS type.
Conclusions: SFN is a common feature in adults with EDS. Skin biopsy could be considered an
additional diagnostic tool to investigate pain manifestations in EDS. Neurology®2016;87:155–159
GLOSSARY
cEDS 5 classic Ehlers-Danlos syndrome; DN4 5 Douleur Neuropathique 4; EDS 5 Ehlers-Danlos syndrome; hEDS 5
hypermobility Ehlers-Danlos syndrome; IENFD 5 intraepidermal nerve fiber density; JHS 5 joint hypermobility syndrome;
NRS 5 Numeric Rating Scale; SFN 5 small fiber neuropathy; SFN-SIQ 5 Small Fiber Neuropathy and Symptoms Inventory
Questionnaire; SNAP 5 sensory nerve action potential; vEDS 5 vascular Ehlers-Danlos syndrome.
Ehlers-Danlos syndrome (EDS) is an umbrella term for different heritable soft connective tissue
disorders mainly characterized by generalized joint hypermobility, skin texture abnormalities,
and visceral and vascular fragility or dysfunctions. Current nosology identifies 6 major EDS var-
iants, with the hypermobility (hEDS), classic (cEDS), and vascular (vEDS) types being the most
common.1 More recently, segregation studies introduced and demonstrated the overlap between
hEDS and the joint hypermobility syndrome (JHS).2 The diagnosis of EDS is confirmed by
molecular tools in most types except JHS/hEDS, which remains a clinical diagnosis based on
available criteria.3
Pain is common in various EDS types, particularly JHS/hEDS,4 and its pathogenesis is mostly
unknown. The natural history of pain in JHS/hEDS is protean with a recurrent/migratory onset
of arthralgias in childhood and a slow progression in an evolving widespread chronic pain syn-
drome in adults and elders. The coexistence of burning sensation, paresthesias, allodynia, cramps,
and diffuse myalgia has suggested a neuropathic component that was recently investigated in 44
patients using a questionnaire study.5 Compression and axonal neuropathies could be more
common in EDS2 and have a role in hyperalgesia associated with JHS/hEDS.6 Some pain features
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in patients with EDS suggest the involvement
of small nerve fibers that has never been inves-
tigated before.
To address this issue, we investigated
a cohort of adult patients with EDS through
clinical, neurophysiologic, and skin biopsy ex-
aminations. Our findings revealed that small
fiber neuropathy (SFN) is part of the clinical
picture and could explain the high rate of neu-
ropathic pain in EDS.
METHODS We consecutively screened and enrolled adult pa-
tients (age $18 years) diagnosed with 3 of the most common
EDS variants according to available criteria1,7 from those attend-
ing specialized clinics, regardless of disease severity. The diagnosis
was confirmed by molecular testing for cEDS and vEDS. All
patients underwent laboratory tests including fasting glucose,
glycated hemoglobin, serum electrophoresis, vitamin B12, blood
cell count, hepatitis B and C, malignancies, and immune-
mediated disease screening to rule out known causes of SFN.8
We excluded patients with other known causes of SFN, with
bleeding disorders, or on anticoagulant treatment. We recorded
sensory symptoms and signs, and diagnosed neuropathic
pain according to the Douleur Neuropathique 4 (DN4) and
ID Pain questionnaires. We defined neuropathic pain in
participants whose DN4 score was $4. We scored pain severity
using the 11-point Likert Pain Intensity Numeric Rating Scale
(NRS). We administered the Small Fiber Neuropathy and
Symptoms Inventory Questionnaire (SFN-SIQ) to all the
patients.9 The SFN-SIQ is a 13-item tool that assesses
autonomic symptoms (e.g., changes in sweating pattern,
presence of diarrhea, constipation, urinary tract problems like
hesitation and incontinence, dry eyes, dry mouth, dizziness
when standing up, palpitations, hot flashes) and pain symptoms
(e.g., sensitive leg skin, burning feet, sheet intolerance, and
restless legs at night). Each item is scored on a 4-point Likert
scale (0, never present; 1, sometimes; 2, often; and 3, always
present).
All patients underwent sural sensory nerve action potential
(SNAP) amplitude (normal value.6 mV) and conduction veloc-
ity (.42 m/s) using surface recording electrodes with standard
placement and cutaneous temperature control above 328C.10 Pa-
tients underwent skin biopsy at the distal leg, 10 cm above the
lateral malleolus within the area of sural nerve innervation using
a disposable 3-mm punch under sterile condition after local anes-
thesia with spray ice. The procedure does not need suture. The
immunostaining processing was performed following published
guidelines using polyclonal anti–protein gene product 9.5 anti-
bodies (Ultraclone, Isle of Wight, UK).11 Briefly, specimens were
fixed (2% paraformaldehyde–lysine–sodium periodate, 48C over-
night), cryoprotected, and serially cut with a cryostat. Each 3-mm
punch biopsy yielded about 45 vertical 50-mm sections. Count of
dermal-epidermal junction crossing fibers for assessing the density
of intraepidermal nerve fiber (IENFD) per millimeter was per-
formed on 3 nonconsecutive central sections (e.g., nos. 25, 27,
29) by bright-field microscopy using a stereology workstation
(Olympus BX50, Tokyo, Japan; PlanApo oil-objective
40 3/NA 5 1.0). IENFD was compared to sex- and age-
adjusted normative values.12
Standard protocol approvals, registrations, and patient
consents. The local ethics committee approved the study and
each participant gave written informed consent before
enrollment.
Statistical analysis. Data were presented using descriptive sta-
tistics and comparison between groups performed using paramet-
ric or nonparametric statistics where appropriate. Analyses were
carried out using Stata 9 software.
RESULTS We screened 25 adult patients, including
21 with JHS/hEDS, 3 with vEDS (2 harboring the
c.134711G.A mutation and one the c.620G.C
Figure Small Fiber Neuropathy and Symptoms Inventory Questionnaire features
Percentage of patients for each of the 13 items. The cohort includes 24 patients with Ehlers-Danlos syndrome.
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mutation in COL3A1), and one with cEDS (harbor-
ing the c.1165-2A.G mutation in COL5A1). We
excluded one patient with JHS/hEDS and known
celiac disease. We eventually enrolled 24 patients
(23 women, 1 man) without any risk factor for
SFN. All patients except one (no. 21, woman, asymp-
tomatic) complained of pain that was initially limited
to the joints then followed by paresthesias or burning
pain in hands and feet in addition to a fairly constant
and severe diffuse musculoskeletal pain. Three pa-
tients reported paresthesias alone, whereas 20 patients
complained of burning sensation with variable inten-
sity predominantly distributed to hands and feet.
Nine patients reported itch causing compulsive
scratching. Preferential distribution of itch included
the back, lower limbs, and more rarely forearms
(2 patient) and scalp (1 patient) (figure). Twenty-
three (95%) patients had neuropathic pain
according to the DN4 questionnaire and at least
probable neuropathic pain according to the ID Pain
questionnaire. Nineteen (79%) patients complained
of at least moderate pain (NRS $4), and among
these, 11 (45%) had severe pain (NRS $7). Most
patients referred frequent cramps (83%). Deep
tendon reflexes were normal in all patients except in
2 patients showing reduced ankle reflexes. Vibration
Table IENFD, DN4, ID Pain, NRS, and SFN-SIQ scores and neuropathic pain symptom features in patients with EDS
Patient Age, y EDS type Gene/mutation IENFD
IENFD
5th cutoff DN4 ID Pain NRS SFN-SIQ Symptoms/distribution
1 48 vEDS COL3A1/c.134711 G.A 1.0 5.7 5 3 7 7 Burning pain/thighs; pruritus/back and lower
limbs
2 43 vEDS COL3A1/c.134711 G.A 4.2 5.7 4 2 4 12 Burning pain/hands and feet
3 43 vEDS COL3A1/c.620 G.C 4.2 5.7 4 3 3 11 Burning pain/hands and feet
4 45 cEDS COL5A1/c.1165-2A.G 3.3 4.4 5 3 3 5 Burning pain/hands and feet; reduced ankle
reflex
5 44 JHS/hEDS Unknown 2.7 5.7 5 3 7 12 Burning pain/hands and feet; pruritus/back
6 39 JHS/hEDS Unknown 0.6 7.1 4 2 8 9 Paresthesias/hands and feet
7 54 JHS/hEDS Unknown 2.4 4.3 8 4 8 13 Burning pain/hands and feet; pruritus/diffuse
8 43 JHS/hEDS Unknown 2.1 5.7 5 4 8 12 Burning pain/feet
9 61 JHS/hEDS Unknown 1.4 3.2 7 4 8 10 Paresthesias/hands
Pruritus/diffuse
10 56 JHS/hEDS Unknown 1.2 4.3 6 4 4 11 Burning pain/hands and feet; pruritus/diffuse
11 37 JHS/hEDS Unknown 2.9 7.1 6 2 7 11 Burning pain/hands and feet
12 49 JHS/hEDS Unknown 1.7 5.7 6 4 9 11 Burning pain/thighs
13 47 JHS/hEDS Unknown 1.2 5.7 7 5 7 11 Burning pain/hands and feet; pruritus/diffuse
14 42 JHS/hEDS Unknown 1.8 5.7 5 2 2 8 Paresthesias/feet
15 37 JHS/hEDS Unknown 4.1 7.1 6 4 6 12 Burning pain/stockings distribution till knee;
pruritus/shins
16 32 JHS/hEDS Unknown 4.7 7.1 5 3 5 12 Burning pain/stockings distribution until knee
17 41 JHS/hEDS Unknown 1.1 5.7 5 3 4 12 Burning pain/hands and feet
18 38 JHS/hEDS Unknown 3 7.1 4 3 5 11 Burning pain/scalp and feet; pruritus/scalp,
forearms, and calves
19 48 JHS/hEDS Unknown 4.4 5.7 7 4 9 10 Burning pain/face, hands, and feet; reduced
ankle reflex
20 29 JHS/hEDS Unknown 2.6 8.4 5 3 5 11 Burning pain/hands and feet; pruritus/
forearms, knee, and calves
21 25 JHS/hEDS Unknown 3 8.4 0 0 0 0 No symptoms
22 46 JHS/hEDS Unknown 2.8 5.7 4 3 3 13 Burning pain/hands and feet
23 55 JHS/hEDS Unknown 2.5 4.3 6 4 9 9 Burning pain/hands and feet
24 44 JHS/hEDS Unknown 4.4 7.1 4 3 5 10 Burning pain/feet
Abbreviations: cEDS 5 classic Ehlers-Danlos syndrome; DN4 5 Douleur Neuropathique 4; EDS 5 Ehlers-Danlos syndrome; IENFD 5 intraepidermal nerve
fiber density; IENFD cutoff 5 5th percentile of sex and age-adjusted normative values; JHS/hEDS 5 joint hypermobility syndrome/hypermobility Ehlers-
Danlos syndrome; NRS 5 Numeric Rating Scale; SFN-SIQ 5 Small Fiber Neuropathy Symptoms Inventory Questionnaire (number of symptoms reported by
patients is shown); vEDS 5 vascular Ehlers-Danlos syndrome.
The last column reports neuropathic symptom features and distribution. All patients showed a reduction of IENFD compared to sex- and age-adjusted
normative values.
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sensation measured using the 128-Hz graded Rydel-
Seiffer tuning fork was normal at distal and proximal
sites in all patients according to normative values.13
No patient reported episodes of postural orthostatic
tachycardia syndrome. All patients except the only
asymptomatic one (no. 21) reported 7 or more
symptoms on the SFN-SIQ (table). Sensitive skin
and restless legs were the most common complaints,
reported by 92% of patients, followed by autonomic
symptoms such as dry eyes, dry mouth, palpitation,
and gastrointestinal disturbances, reported by 83% of
patients. Sural SNAP and conduction velocity were
normal in all patients. Conversely, skin biopsy
revealed a decrease of IENFD as compared with
age- and sex-adjusted normative values in all
patients (table). We did not find any correlation
among IENFD, severity of pain, and diagnostic
classification of EDS.
DISCUSSION Most patients with EDS complain of
chronic or recurrent pain that causes a relevant reduc-
tion in quality of life.4 While nociceptive musculo-
skeletal pain can find an explanation in ligament
laxity with secondary joint instability predisposing
to macrotraumatisms and microtraumatisms, the
underlying causes of neuropathic pain have remained
unaddressed. Besides painful symptoms, most pa-
tients have moderate to severe autonomic distur-
bances in several domains of SFN-SIQ, according
to previous studies focusing on extra-articular
manifestations.14
Our study first described small nerve fiber pathol-
ogy in patients with EDS. Indeed, all our patients
showed a significant decrease of IENFD consistent
with the diagnosis of SFN according to published
guidelines.12 IENFs are peripheral nociceptors and
their degeneration is a diagnostic hallmark of painful
SFN. Nevertheless, the mechanisms underlying the
degeneration of small fibers in most of the acquired
and genetic conditions known to be associated with
SFN, now including also EDS, remain unexplained.8
The lack of correlation between IENFD, pain
severity, and pain features has been reported in
SFN. However, neuropathic pain is a frequent feature
in pathologic conditions affecting exclusively or pre-
dominantly small nerve fibers, more than in other
types of sensory neuropathies involving large nerve fi-
bers.8 Moreover, the improvement of IENFD is a sign
of recovery from neuropathy and it correlates with
a reduction of pain intensity in SFN.15–17 Therefore,
our current understanding is that skin biopsy can
support the diagnosis of neuropathies more likely
associated with neuropathic pain, in which small fi-
bers are predominantly or exclusively impaired. The
findings reported in the current work would include
EDS among these conditions. However, whether
IENF loss itself causes the development and mainte-
nance of neuropathic pain or is just a marker of dam-
age causing neuropathic pain remains unknown.
We did not find any significant differences
between pain severity and IENFD among the differ-
ent subtypes of EDS. However, the number of pa-
tients with vEDS and cEDS was small and the
homogeneous pattern of IENFD decrease among dif-
ferent EDS subtypes needs confirmation in larger co-
horts. Nevertheless, our findings are in keeping with
previous reports of pain incidence in cEDS and JHS/
hEDS.5 Only one patient (no. 21) did not complain
of pain despite reduced IENFD. The reason for such
difference in the clinical picture compared with the
other patients remains unknown, though younger age
could be an explanation. EDS, and particularly JHS/
hEDS, predominantly affects women, with a relative
prevalence of about 70%.2 Our cohort was relatively
small and composed of all women except for one
man. Therefore, despite the finding of SFN in all
patients, we cannot exclude sex-related differences.
Our study demonstrated that, regardless the diag-
nostic subtype, SFN is a feature of EDS. This finding
provides a clue to the diagnosis of neuropathic pain in
EDS and supports the investigation of small nerve
fiber pathology for the characterization of pain symp-
toms in such a heterogeneous group of disorders.
Finally, we emphasized the burden of extra-articular
manifestations including painful and autonomic dis-
turbances in EDS.
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